Horizon Capital invests in Viseven, a Ukrainian martech provider

Horizon Capital’s Growth Fund IV has invested in Viseven, a provider of marketing technology solutions and services in the pharmaceutical and life sciences industries. The investment amount was not disclosed.

• Viseven was co-founded in 2009 in Zhytomyr by Nataliya Andreychuk, Vyacheslav Vasylenko, and Roman Vasylenko. Currently, the company has more than 50 customers in the field of pharmaceuticals and life sciences, including 20 top companies: Abbott, AbbVie, Amgen, Bayer, Biogen, Ipsen, Lilly, Novo Nordisk, Servier Laboratories, etc.
• The startup develops content for various devices and channels, mobile medical applications, websites, landing pages, designs email templates, and creates pharmaceutical digital services for brand promotion. Viseven’s team consists of more than 700 specialists in the US, Canada, Argentina, Estonia, France, Spain, Germany, Poland, Ukraine, and India. 

About Horizon Capital

• Horizon Capital is a private equity firm with over $1.5 billion in AUM from investors with a capital base exceeding $630 billion. The firm’s investment strategy focuses on export-oriented businesses in Ukraine and Moldova. Horizon Capital-managed funds have invested in over 170 companies employing over 80,000 people.

I’m delighted to announce Horizon Capital’s investment in another global tech champion out of Ukraine, in a sign of enduring resilience for our Region. Nataliya is a truly inspiring leader and we are privileged to be backing the Viseven team with growth capital in this next chapter of their high-growth journey,

Lenna Koszarny, Founding Partner and CEO at Horizon Capital, commented.

• This transaction is the third investment from the latest fund, Horizon Capital Growth Fund IV (HCGF IV), which reached $328 million at its most recent closing held in December 2023.